An economic evaluation of antihypertensive therapies based on clinical trials
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/19700 |
Resumo: | OBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure (in mm Hg) at the end of a 12-month study period. RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the same pattern when the purchase price of the lower-cost medication was used. CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and the current treatment for the HT3 group. |
id |
USP-19_d41a2eafbeda78c36c1cfe96594856bf |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/19700 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
An economic evaluation of antihypertensive therapies based on clinical trialsHypertensionPharmacoeconomicsCost-effectivenessAntihypertensive drugsOBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure (in mm Hg) at the end of a 12-month study period. RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the same pattern when the purchase price of the lower-cost medication was used. CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and the current treatment for the HT3 group.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1970010.6061/clinics/2012(01)07Clinics; Vol. 67 No. 1 (2012); 41-48Clinics; v. 67 n. 1 (2012); 41-48Clinics; Vol. 67 Núm. 1 (2012); 41-481980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/19700/21764Tsuji, Rosana Lima GarciaSilva, Giovanio Vieira daOrtega, Katia CoelhoBerwanger, OtavioMion Júnior, Decioinfo:eu-repo/semantics/openAccess2012-05-24T19:09:29Zoai:revistas.usp.br:article/19700Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-24T19:09:29Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
An economic evaluation of antihypertensive therapies based on clinical trials |
title |
An economic evaluation of antihypertensive therapies based on clinical trials |
spellingShingle |
An economic evaluation of antihypertensive therapies based on clinical trials Tsuji, Rosana Lima Garcia Hypertension Pharmacoeconomics Cost-effectiveness Antihypertensive drugs |
title_short |
An economic evaluation of antihypertensive therapies based on clinical trials |
title_full |
An economic evaluation of antihypertensive therapies based on clinical trials |
title_fullStr |
An economic evaluation of antihypertensive therapies based on clinical trials |
title_full_unstemmed |
An economic evaluation of antihypertensive therapies based on clinical trials |
title_sort |
An economic evaluation of antihypertensive therapies based on clinical trials |
author |
Tsuji, Rosana Lima Garcia |
author_facet |
Tsuji, Rosana Lima Garcia Silva, Giovanio Vieira da Ortega, Katia Coelho Berwanger, Otavio Mion Júnior, Decio |
author_role |
author |
author2 |
Silva, Giovanio Vieira da Ortega, Katia Coelho Berwanger, Otavio Mion Júnior, Decio |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Tsuji, Rosana Lima Garcia Silva, Giovanio Vieira da Ortega, Katia Coelho Berwanger, Otavio Mion Júnior, Decio |
dc.subject.por.fl_str_mv |
Hypertension Pharmacoeconomics Cost-effectiveness Antihypertensive drugs |
topic |
Hypertension Pharmacoeconomics Cost-effectiveness Antihypertensive drugs |
description |
OBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. METHODS: Hypertension treatment costs were estimated on the basis of the purchase prices of the antihypertensive medications, and effectiveness was measured as the reduction in systolic blood pressure and diastolic blood pressure (in mm Hg) at the end of a 12-month study period. RESULTS: When the purchase price of the brand-name medication was used to calculate the cost, the traditional treatment presented a lower cost-effectiveness ratio [US$/mm Hg] than the current treatment in the HT1-2 group. In the HT3 group, however, there was no difference in cost-effectiveness ratio between the traditional treatment and the current treatment. The cost-effectiveness ratio differences between the treatment regimens maintained the same pattern when the purchase price of the lower-cost medication was used. CONCLUSIONS: We conclude that the traditional treatment is more cost-effective (US$/mm Hg) than the current treatment in the HT1-2 group. There was no difference in cost-effectiveness between the traditional treatment and the current treatment for the HT3 group. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/19700 10.6061/clinics/2012(01)07 |
url |
https://www.revistas.usp.br/clinics/article/view/19700 |
identifier_str_mv |
10.6061/clinics/2012(01)07 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/19700/21764 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 67 No. 1 (2012); 41-48 Clinics; v. 67 n. 1 (2012); 41-48 Clinics; Vol. 67 Núm. 1 (2012); 41-48 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222758267781120 |